International Stem Cell Corporation (OTCBB: ISCO) today announced
the Company's near-term marketing plans for products manufactured by its
Lifeline Skin Care™ (Lifeline) subsidiary. Following the highly
successful launch in late 2010 of Lifeline's first two products with
sales that greatly exceeded expectations, Lifeline has now commenced a
new phase in the marketing plan for its skin care products.
The first step in these initiatives is a series of briefings being
conducted in New York City this week with editors at beauty magazines
whose readership reflects the target user base for Lifeline's anti-aging
skin care products. This will be followed by a series of targeted email
offerings developed by Lifeline's marketing partner, The Mauldin
Companies, culminating in a larger offering in June.
Lifeline's anti-aging products were developed by ISCO's scientific
research team in collaboration with internationally recognized cosmetic
experts. The first two products, a Day Serum and a Night Serum, both
contain an extract from ISCO's proprietary human parthenogenetic stem
cells which, in combination with vitamin complexes, provides major
rejuvenating effects, including improvement in skin tone and elasticity,
and improvement in the appearance of fine lines and wrinkles. These
effects have been substantiated by clinical studies performed at
industry-leading independent testing organizations.
Lifeline's premium product line includes the Recovery Night Moisture
Serum and the Defensive Day Moisture Serum/SPF-15. These products are
most commonly ordered together in a 2-pack, and can be purchased by
visiting Lifeline's website at www.lifelineskincare.com.
The products are also available at selected luxury spas and physician's
offices in the United States.
Dr. Ruslan Semechkin, President and CEO of Lifeline Skin Care, added
that Lifeline plans to launch additional skin care products later this
year, including an eye cream formulated with a proprietary stem cell
derivative and a cleanser.
Lifeline is focusing its marketing on direct-to-consumer channels to
highly targeted audiences with traditional print and media promotions
planned for later in the year. The Company's goal is to generate
favorable word-of-mouth through a network of satisfied customers,
thereby building a community of users based on their shared experience
of success with Lifeline's proprietary anti-aging products.
Ken Aldrich, Co-founder and Chairman of Lifeline's parent company,
International Stem Cell Corporation, said, "The success of Lifeline Skin
Care demonstrates that we can make a positive difference in people's
lives today, while also providing an important source of revenue to
support ISCO's development of stem cell therapies that may in the future
result in treatment for many widespread human diseases."
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells and the development and
commercialization of cell-based research and cosmetic products. ISCO's
core technology, parthenogenesis, results in the creation of pluripotent
human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical
issues associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenic, homozygous stem
cell line that can be a source of therapeutic cells with minimal immune
rejection after transplantation into hundreds of millions of individuals
of differing genders, ages and racial background. This offers the
potential to create the first true stem cell bank, UniStemCell™. ISCO
also produces and markets specialized cells and growth media for
therapeutic research worldwide through its subsidiary Lifeline Cell
Technology, and cell-based skin care products through its subsidiary
Lifeline Skin Care. More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click
on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, product introduction
and marketing plans and related support, the potential benefits of
products, and other opportunities for the company and its subsidiaries,
along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as
"will," "believes," "plans," "anticipates," "expects," "estimates,")
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products and the management of
collaborations, regulatory approvals, need and ability to obtain future
capital, application of capital resources among competing uses, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update forward-looking statements.
International Stem Cell Corporation Kenneth
C Aldrich, Chairman 760-940-6383 kaldrich@intlstemcell.com or Lifeline
Skin Care, Inc. Ruslan Semechkin, Ph.D., President & CEO Vice
President, ISCO ras@intlstemcell.com or Lippert/Heilshorn
& Associates Don Markley 310-691-7100 dmarkley@lhai.com |